Predictive value of amino acids in the treatment of major depression with fluvoxamine

Massimo C. Mauri, Luigi Boscati, Lucia S. Volonteri, Marta E. Scalvini, C. P C Steinhilber, Valerio Laini, Federica Zamberlan

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Sixteen outpatients (mean age ± SD 50.18 ± 11.55 years; 11 females and 5 males) affected by major depression without melancholia (DSM-IV) were included in the study. The control group consisted of 11 healthy volunteers (mean age ± SD 39.90 ± 13.39 years; 2 females and 9 males). Patients were treated with fluvoxamine (FVX) 100-300 mg daily. Clinical assessment was performed using the Hamilton Rating Scales for Anxiety and Depression (HRS-A; HRS-D) and the Clinical Global Impression Scale (CGI) at basal time (T0), after 4 weeks and after 8 weeks (T8). Plasma and platelet amino acid levels were determined at T0 in all the subjects and also at T8 in depressed patients. A significant clinical improvement was observed in depressed patients according to the HRS-A (p = 0.004), HRS-D (p = 0.008) and CGI (p = 0.002). A negative correlation (r = -0.53, p = 0.049) was found between platelet levels of valine and HRS-D improvement rate. Patients showed significantly higher tyrosine/large neutral amino acids (LNAAs) and lower tryptophan/LNAAs, ratios which could represent an index of good response to a serotonergic drug like FVX.

Original languageEnglish
Pages (from-to)134-138
Number of pages5
JournalNeuropsychobiology
Volume44
Issue number3
DOIs
Publication statusPublished - 2001

Fingerprint

Fluvoxamine
Depression
Neutral Amino Acids
Amino Acids
Blood Platelets
Serotonin Agents
Valine
Therapeutics
Depressive Disorder
Tryptophan
Diagnostic and Statistical Manual of Mental Disorders
Tyrosine
Healthy Volunteers
Outpatients
Anxiety
Control Groups

Keywords

  • Amino acids
  • Fluvoxamine
  • Major depression

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuroscience(all)
  • Psychology(all)

Cite this

Mauri, M. C., Boscati, L., Volonteri, L. S., Scalvini, M. E., Steinhilber, C. P. C., Laini, V., & Zamberlan, F. (2001). Predictive value of amino acids in the treatment of major depression with fluvoxamine. Neuropsychobiology, 44(3), 134-138. https://doi.org/10.1159/000054933

Predictive value of amino acids in the treatment of major depression with fluvoxamine. / Mauri, Massimo C.; Boscati, Luigi; Volonteri, Lucia S.; Scalvini, Marta E.; Steinhilber, C. P C; Laini, Valerio; Zamberlan, Federica.

In: Neuropsychobiology, Vol. 44, No. 3, 2001, p. 134-138.

Research output: Contribution to journalArticle

Mauri, MC, Boscati, L, Volonteri, LS, Scalvini, ME, Steinhilber, CPC, Laini, V & Zamberlan, F 2001, 'Predictive value of amino acids in the treatment of major depression with fluvoxamine', Neuropsychobiology, vol. 44, no. 3, pp. 134-138. https://doi.org/10.1159/000054933
Mauri MC, Boscati L, Volonteri LS, Scalvini ME, Steinhilber CPC, Laini V et al. Predictive value of amino acids in the treatment of major depression with fluvoxamine. Neuropsychobiology. 2001;44(3):134-138. https://doi.org/10.1159/000054933
Mauri, Massimo C. ; Boscati, Luigi ; Volonteri, Lucia S. ; Scalvini, Marta E. ; Steinhilber, C. P C ; Laini, Valerio ; Zamberlan, Federica. / Predictive value of amino acids in the treatment of major depression with fluvoxamine. In: Neuropsychobiology. 2001 ; Vol. 44, No. 3. pp. 134-138.
@article{6fc2915b51ad4f1fb0f78878bcea967b,
title = "Predictive value of amino acids in the treatment of major depression with fluvoxamine",
abstract = "Sixteen outpatients (mean age ± SD 50.18 ± 11.55 years; 11 females and 5 males) affected by major depression without melancholia (DSM-IV) were included in the study. The control group consisted of 11 healthy volunteers (mean age ± SD 39.90 ± 13.39 years; 2 females and 9 males). Patients were treated with fluvoxamine (FVX) 100-300 mg daily. Clinical assessment was performed using the Hamilton Rating Scales for Anxiety and Depression (HRS-A; HRS-D) and the Clinical Global Impression Scale (CGI) at basal time (T0), after 4 weeks and after 8 weeks (T8). Plasma and platelet amino acid levels were determined at T0 in all the subjects and also at T8 in depressed patients. A significant clinical improvement was observed in depressed patients according to the HRS-A (p = 0.004), HRS-D (p = 0.008) and CGI (p = 0.002). A negative correlation (r = -0.53, p = 0.049) was found between platelet levels of valine and HRS-D improvement rate. Patients showed significantly higher tyrosine/large neutral amino acids (LNAAs) and lower tryptophan/LNAAs, ratios which could represent an index of good response to a serotonergic drug like FVX.",
keywords = "Amino acids, Fluvoxamine, Major depression",
author = "Mauri, {Massimo C.} and Luigi Boscati and Volonteri, {Lucia S.} and Scalvini, {Marta E.} and Steinhilber, {C. P C} and Valerio Laini and Federica Zamberlan",
year = "2001",
doi = "10.1159/000054933",
language = "English",
volume = "44",
pages = "134--138",
journal = "Neuropsychobiology",
issn = "0302-282X",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Predictive value of amino acids in the treatment of major depression with fluvoxamine

AU - Mauri, Massimo C.

AU - Boscati, Luigi

AU - Volonteri, Lucia S.

AU - Scalvini, Marta E.

AU - Steinhilber, C. P C

AU - Laini, Valerio

AU - Zamberlan, Federica

PY - 2001

Y1 - 2001

N2 - Sixteen outpatients (mean age ± SD 50.18 ± 11.55 years; 11 females and 5 males) affected by major depression without melancholia (DSM-IV) were included in the study. The control group consisted of 11 healthy volunteers (mean age ± SD 39.90 ± 13.39 years; 2 females and 9 males). Patients were treated with fluvoxamine (FVX) 100-300 mg daily. Clinical assessment was performed using the Hamilton Rating Scales for Anxiety and Depression (HRS-A; HRS-D) and the Clinical Global Impression Scale (CGI) at basal time (T0), after 4 weeks and after 8 weeks (T8). Plasma and platelet amino acid levels were determined at T0 in all the subjects and also at T8 in depressed patients. A significant clinical improvement was observed in depressed patients according to the HRS-A (p = 0.004), HRS-D (p = 0.008) and CGI (p = 0.002). A negative correlation (r = -0.53, p = 0.049) was found between platelet levels of valine and HRS-D improvement rate. Patients showed significantly higher tyrosine/large neutral amino acids (LNAAs) and lower tryptophan/LNAAs, ratios which could represent an index of good response to a serotonergic drug like FVX.

AB - Sixteen outpatients (mean age ± SD 50.18 ± 11.55 years; 11 females and 5 males) affected by major depression without melancholia (DSM-IV) were included in the study. The control group consisted of 11 healthy volunteers (mean age ± SD 39.90 ± 13.39 years; 2 females and 9 males). Patients were treated with fluvoxamine (FVX) 100-300 mg daily. Clinical assessment was performed using the Hamilton Rating Scales for Anxiety and Depression (HRS-A; HRS-D) and the Clinical Global Impression Scale (CGI) at basal time (T0), after 4 weeks and after 8 weeks (T8). Plasma and platelet amino acid levels were determined at T0 in all the subjects and also at T8 in depressed patients. A significant clinical improvement was observed in depressed patients according to the HRS-A (p = 0.004), HRS-D (p = 0.008) and CGI (p = 0.002). A negative correlation (r = -0.53, p = 0.049) was found between platelet levels of valine and HRS-D improvement rate. Patients showed significantly higher tyrosine/large neutral amino acids (LNAAs) and lower tryptophan/LNAAs, ratios which could represent an index of good response to a serotonergic drug like FVX.

KW - Amino acids

KW - Fluvoxamine

KW - Major depression

UR - http://www.scopus.com/inward/record.url?scp=0035741997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035741997&partnerID=8YFLogxK

U2 - 10.1159/000054933

DO - 10.1159/000054933

M3 - Article

VL - 44

SP - 134

EP - 138

JO - Neuropsychobiology

JF - Neuropsychobiology

SN - 0302-282X

IS - 3

ER -